Life Sciences Archive » September, 2022

Life Sciences - September, 2022

319 articles

• 3rd Circ. Orders Sentence Redo In $95M Drug Fraud Case
• The 5 Biggest Cases This Supreme Court Term
• $178M Verdict Against Novartis Stands But Can't Be Tripled
• Fla. Man's Silence Keeps Gilead's NY Counterfeiting Suit Alive
• BakerHostetler Accused Of Fraud In $100M Bankruptcy Suit
• Detroit Cannabis Licensing Unfair To Non-Residents, Suit Says
• Administrator Named In CVS-Walgreens-Walmart Opioid Order
• Law360's The Term: A New Normal For The Supreme Court?
• Health Hires: Nelson Mullins, Lyell Immunopharma
• No Signs Of Supreme Court's Conservatives Slowing Down
• How Well Do You Know Supreme Court History?
• UnitedHealth Merger Loss Is One Step In DOJ's Long Game
• Judge Adopts Report, Giving Medical Lab, Insurer Partial Wins
• UK Litigation Roundup: Here's What You Missed In London
• Justice Ketanji Brown Jackson Takes Bench, Makes History
• Keys To A 9-0 High Court Win: Practicality Over Perfection
• FTC Accuses Pesticide Giants Of 'Pay-To-Block' Scheme
• 5 Firms Guide $834M Chinese Biopharma SPAC Merger
• IP Forecast: Philip Morris Looks To Snuff Out ITC Ban
• Monster Wins $293M Verdict Against VPX In False Ad Trial
• Stimwave Gets Del. Ch. 11 OK For $124M Auction Offer
• High Court Halts Generic Gilenya As Novartis Appeals IP Loss
• 6th Circ. Affirms Ky. Clerk Liable In Gay Marriage License Suit
• Technology Co. Sues Insurers Over Wire Fraud Losses
• What New Bar Exam Means For Law Students And Schools
• Fed. Circ. Affirms PTAB Save Of Merck Diabetes Drug Patent
• Centene To Pay $14M To Settle Mass. Medicaid Fraud Claims
• C.R. Bard Can't Escape Trial In Illinois Pelvic Mesh Suit
• What USPTO's Disclosure Duties Notice Says And Doesn't Say
• Ill. City Says It Was 'Kicked' By Express Scripts' Doc Dump
• Chinese Pharma Co. Seeks OK Of $40M Arbitral Award
• Endo Opioid Claimants Question Their Slice Of Ch. 11 Deal
• Medicare's 340B Cuts For 2022 Must End Now, Judge Rules
• Workers Fight Pot Co. Curaleaf's Renewed Bid To Ax Tips Suit
• La. Health Clinic's Ex-CEO Convicted In Medicaid Fraud
• Apple's New Messaging Features Will Complicate E-Discovery
• Novartis Gets Counterclaims Cut From Heart Drug Patent MDL
• Pro-Choice Advocates Say Paxton Subpoena Saga Is His Fault
• Womble Bond Adds DC Partner Amid Patent Hiring Spree
• Paramedical Services Co. Hit With TCPA Suit Over Robocalls
• MVP: Williams & Connolly's David I. Berl
• Recent Cases Guide On Use Of Experts In Employment Trials
• Biogen Whistleblower's $250M Award 'Extraordinary' For FCA
• Fed. Circ. Won't Halt Gilenya Generics During Novartis Appeal
• Fed. Circ. Temporarily Pauses Launch Of Generic Lexiscan
• Seattle Cafe Drops 9th Circ. Virus Coverage Appeal
• Fastest AG In The West? Paxton Slips Service In Abortion Row
• The High Court Cases Health And Life Sci Attys Are Watching
• COVID-Focused Biotech Firm Eyeing $675M SPAC Merger
• Ex-Receptionist Says MRI Co. Fired Her For Reporting Abuse
• Law Firm Inclusion Efforts Often Overlook Business Staff
• UK Court OKs Stay For Mesh Suits Against Endo Unit
• Colorado High Court Says State Can't Sue Juul Execs
• Indiana Abortion Ban Challenged By Satanic Temple
• Travelers Has No Duty To Defend Northrop Pollution Suit
• Health Care Fraud Among New Philly US Atty's Top Concerns
• 2 Firms Seek $1.25M In Chancery Deal With Biotech Co., CEO
• BioNTech And Pfizer Want CureVac COVID Patents Nixed
• RICO Claims Against Cannabis Cos. Are Evolving
• L'Oreal Must Face False Ad Suit Over Collagen Products
• MVP: White & Case's Adam Acosta
• Biogen Finalizes $900M Deal To End Feds' Kickback Claims
• EEOC Sues Eli Lilly For Age Bias After Exec Touted Millennials
• Women At Ford, GE Outliers In Top Cos.' Wide IP Gender Gap
• Stay Mulled In Del. Suit Targeting Walmart Opioid Damages
• Eli Lilly Off The Hook In Trade Secrets Suit Over Migraine App
• Two Funds Seek Invidior Antitrust Docs In Securities Case
• Reexamining Negative Limitations After Novartis Patent Ruling
• Catching Up With Delaware's Chancery Court
• 3 Recent Cases Highlight Public Nuisance Climate Suits' Flaws
• Biotech Firm Says Competitor Spread Lies About Gender Test
• An Associate's Guide To Rebounding After A Layoff
• Investors Fight Hemp Co.'s Bid To Toss Stock-Drop Suit
• MVP: Quinn Emanuel's David Bilsker And David Perlson
• 3 Questions As Feds Flesh Out New Breach Reporting Rules
• Musk's Dim View Of Patents Ignores Reality For Most Cos.
• Stockholders Reach Far For Damages In Chancery Opioid Suit
• Jury Puts Stryker Biz On Hook For $17.2M In Bone Screw Fight
• J&J Wants 'Rapid Release' Tylenol Class Claims Tossed
• Judge Cuts Some Of Atum's Claims In Gene Therapy IP Row
• Ga. Judge Dismisses Ethylene Oxide Exposure Case
• 9th Circ. Overturns Insurer's Win In ERISA Benefits Suit
• AML Regulation Of Lawyers Is Imminent And Controversial
• Equally Split Full 4th Circ. Affirms Toss Of Allergan FCA Case
• 'I Lost A Lot': Breyer Opens Up On 'Frustrating' Last Term
• Jury Says LabCorp Owes $272M For Infringing Prenatal Test IP
• Bristol-Myers Must Face Celgene Deal Suit In NJ State Court
• J&J Unit Looks To Scrub BIPA Suit Over Skin Care App
• Pfizer Kickback Ruling Shows Drug Copay Program Risks
• UK Litigation Roundup: Here's What You Missed In London
• MVP: Covington's Amy Toro
• Sofia Vergara's Ex-Fiancé Can't Revive Pre-Embryo Suit
• Transplant Co. Hit With Investor Suit Over Bundling Probe
• Stimwave Director Calls For Investigation Of Ch. 11 Sale
• IP Forecast: Tyga's 'Wavy Baby' Shoe Row Goes To 2nd Circ.
• 1st Post-Dobbs Abortion Ban Is Blocked In Indiana
• Rutgers Defeats Challenge To COVID-19 Vaccine Mandate
• Life Sciences-Focused Blank-Check Firm DMB Pulls $75M IPO
• SG Tells Justices To Reject Amgen Patent Enablement Case
• What DOJ Enforcement Shift Means For Life Sciences Cos.
• Weighing Risk And Reward Of Cooperating In FCA Civil Cases
• PTAB Director Review Under Vidal: The First 6 Months
• Merck Gets Win In Patent Suit Over Diabetes Drugs
• Biden Order's New Lens Puts Foreign Transactions In Focus
• Viatris Investor Can Take Merger Suit Back To State Court
• Biopharma Co. Blasts 'Excessive' Fee Bid In Board Pay Case
• Longtime Federal Prosecutor Joins Troutman Pepper In Philly
• FTC Privacy Suit Tests Agency's Regulatory Authority
• Opioid MDL Attys To Get 'Much More Aggressive' As Talks Lag
• Feds Call Holmes' New Trial Bids 'Ploy' To Delay Sentencing
• UnitedHealth-Change Judge Outlines Why DOJ Lost
• Counterclaims Nixed In Drug Price Checker's Antitrust Suit
• Viatris Suppliers Want Out Of J&J Unit's MS Drug IP Suit
• Mass Tort Cases Expose Bankruptcy Courts To New Threats
• 1st Circ. Pick Vows To Apply Dobbs 'Faithfully'
• 1st Circ. Declines To Review Pot Interstate Commerce Ruling
• Key Adaptations For Law Firms Amid Quiet Quitting Movement
• 2nd Circ. Shkreli Atty Ruling Guides On 401(k) Garnishment
• Eli Lilly Seeks Exit From Workers' 401(k) Fees Class Action
• Genentech Agrees To 30K-Strong Class In 401(k) Fees Suit
• Proposed Hemp Tea Class Action Tossed By NJ Judge
• W.Va. AG Eyes $1B Opioid Haul As CVS, Walmart Pay $150M
• Portola Pharma Investors Ink $17.5M Deal Over Stock Declines
• Opana Direct Buyers' Attys Seek $50M Fees After $145M Deal
• CVS Wants NY's Illegal Service Tying Claims Tossed
• Abortion Rights Atty, A 1st Circ. Pick, May Face Tough Hearing
• Judge To Extend Block Of Ohio's 'Heartbeat' Abortion Law
• Fed. Circ. Won't Eye Novartis Case Flipped By Judge Change
• 2 SPACs Will Shut Down After Failed Searches
• FDA Hiding E-Cig Work 'In The Shadows,' Juul Suit Says
• Mylan Flags Claims Court Ruling In $50M Tax Fight At 3rd Circ.
• 3 Reasons Beauty Cos. Should Consider Pursuing Patents
• Fed. Contractor Says Glove Co. Hid Gov't Forced Labor Probe
• Terminix Investor Sues To Stop $6.7B Merger With Rentokil
• Creating A Hybrid Work Policy? Be Intentional And Inclusive
• 'Excessive' Atty Fee Bid In Ranbaxy MDL Slashed By $36M
• Imminent W.Va. Opioid Trial Delayed Amid New Suit, CVS Deal
• J&J's Talc Ch. 11 Case Was Bad Faith, Claimants Tell 3rd Circ.
• LabCorp Infringed Prenatal Test IP, Biotech Biz Tells Jury
• PTAB Wipes Out Cardiovalve's Heart Valve Implant Patent
• Vizgen Can't Escape Harvard, 10x's Patent Suit
• Cannabis Coverage Suit Belongs In Fed. Court, Insurers Say
• Biden Order Renews Spotlight On Advancement Of US Biotech
• Judge Won't Block UnitedHealth's Purchase Of Change
• BakerHostetler, Potter Anderson Trade Barbs In Board Battle
• Catching Up With Delaware's Chancery Court
• Judge Drops Five Plaintiffs From Juul MDL
• A Law Firm's Guide To Humane Layoffs As Recession Looms
• Jury Awards $363M In First Sterigenics Ethylene Oxide Trial
• Canadian Co. Can Exit Hemp Harvesting Machine Dispute
• Report Says 'Pervasive Abuse' Of Patents Boosts Drug Prices
• New CFIUS Order Will Prompt Broader Investment Scrutiny
• 50 Cent Sues Fla. Surgeon Over 'Penile Enhancement' Ads
• Chamber Seeks Biden Ax Of Wider WTO IP Deal
• Vanda Pharma Investors' $11.5M Deal Gets Judge's Initial OK
• US Gov't Sues Barge Insurer For $6.2M Oil Cleanup
• FCA Defendants Should Consider 'Collateral Hope' Defense
• Insurer Refuses To Defend Bakery In Ga. Poisoned Wells Suit
• BakerHostetler Blasts 'Misguided' Subpoena In Board Battle
• Marching In On Patents Under Bayh-Dole Would Gut Startups
• Judge Axes 2 Anti-Seizure Drug Patents, Upholds 3 Others
• 3rd Time May Be The Charm For Florida Cannabis Legalization
• Reverse Mergers Get Another Look As SPACs Decline
• Sterigenics Tells Ill. Jury That Emissions Science On Its Side
• FCA's 'Creative Lawyering' Defense Divides Full 4th Circ.
• Novartis Tells FDA Skinny Labels Won't Work With $3.5B Drug
• IP Forecast: PTAB To Eye Patent Tied To Intel's $2.2B Loss
• 2nd Circ. Won't Push $881M Cannabis IP Fight Into Arbitration
• Sanitizer Co. 4E Brands' Ch. 11 Plan Draws Creditor Objection
• Nev. Judge Orders Pot's Removal From State's Schedule I List
• Claim Construction Lessons In PTAB Fluid Energy Decision
• Shearman Partner Joins Caris Life Sciences As GC
• Fox Rothschild Grows Suburban Philly Outpost With IP Pro
• Boy Scouts Plan Confirmed, Cineworld Hits Ch. 11
• Sidley Adds Co-Founder Of Cooley's Shanghai Office In Calif.
• Drugmaker Akorn To Pay $7.9M For 'Rx-Only' Medicare Claims
• Biden Beefs Up Nat'l Security Evals For Foreign Investments
• Fla. Property Management Co.'s COVID Claims Tossed Again
• Holmes' New Trial Bid Is 'Mt. Everest' Uphill Fight, Attys Say
• Debevoise-Led AIG Spinoff Hits $1.68B In 2022's Biggest IPO
• Real Estate Rumors: UBS, Picus, Buzz Oates
• Faulty Food Engendered Mass Mice Euthanasia, NC Lab Says
• White House Details $2B Biotech Supply Chain Initiative
• Pharma Co. Challenges FDA's 'Uneven' Blood Drug Standards
• Spirit Air Can't Move Ahead With COVID-19 Coverage Suit
• What's Next For DOJ's COVID Enforcement In Health Care
• US Trustee Says Endo Can't Justify $71M In Bonus Pay
• White & Case-Led Apollomics To Go Public Via SPAC Merger
• Diagnostic Biz Investor Sues To Stop $1.53B Take-Private Sale
• Multiple Sclerosis Drug Kickback Case Against Novartis Axed
• Ohio Judge Temporarily Blocks 6-Week State Abortion Ban
• Walmart Settles W.Va. Opioid Case As Latest Trial Looms
• Sanofi Puerto Rico Unit Excused From Insulin Antitrust Case
• Loeb & Loeb Picks Up Regulatory Attorney In DC
• Learning From Trump And Bannon Discovery Strategies
• Abbott Unit Beats Ex-Worker's Appeal After Bias Trial Win
• Tulane, Insurer Gear Up For Trial In COVID-19 Coverage Row
• Sen. Graham's Federal Abortion Ban Gets GOP Cold Shoulder
• ITC Blocks Chinese Biotech Imports In Win For Ventria
• Women Sue Over Alleged Inaccurate Ovulation Test Kits
• 9th Circ. Says FDA Has Dibs On Copycat Drug Suits
• Gold Mine Ordered To Pay $500K For Polluting River In Colo.
• How To Minimize Risk When Launching Smart Medical Devices
• Green Groups Seek To Restart Fluoridated Water Risks Case
• Determining Assignor Estoppel After Hologic Patent Ruling
• Surgical Assistant Group Sues Board Over Accreditation
• AI Patent Survives PTAB Review After Getting Axed In WDTX
• Chancery Won't Delay Review Of Ionis Pharma Pay Suit Deal
• Waco IP Atty Calls Pilot License His 'Secret Weapon'
• CBD Co. Can't Slip Co-Founder's Suit Over $5M Tax Bill
• AstraZeneca Beats Investors' COVID Vaccine Suit For Good
• Korean Co. Can't Be First To Invent CRISPR, PTAB Told
• Customer Pledges, Lack Of Rivals Sunk FTC's Illumina Case
• FTC Asks About Credibility In Appeal Over Altria's Juul Deal
• Biden Aims To Boost Biotech In Latest Supply Chain Fix
• Gilead Settles HIV Drugs Patent Suit On Eve Of Bench Trial
• Ambry Genetics To Pay $12.25M To End Data Breach Suit
• Solicitor General Tells Justices To Pass On FCA Pleading Rule
• Lewis Brisbois Adds Toxic Tort Pros To Philly Office
• Endo Seeks Injunction To Pause Government Opioid Suits
• The Risks In Lateral Hiring, And How To Avoid Them
• Inside The Collapse Of A Pioneering Opioid Case For DOJ
• Abbott Infant Formula MDL Gets Co-Lead Plaintiffs' Attys
• Pfizer's $5.4B Deal To Acquire Drugmaker Faces Investor Suit
• WTO Dispute Roundup: Same Stalemate, New Solution
• Florida Pharma Co. Settles Drug Control Suit For $14.25M
• What Psychedelic Lawyers Can Learn From Pot Legalization
• Drugmaker Kickback Deal Isn't A Covered Loss, 7th Circ. Told
• AIG Spinoff's $1.8B Offering Kicks Off September IPO Lineup
• DLA Piper Adds FDA Adviser To Partner Ranks
• Medtronic Investors Sue Over Insulin Pump Recall, FDA Letter
• Patent Eligibility Reform May Require A Legislative Approach
• Health Hires: Bass Berry & Sims, Curebase
• 3rd Circ. Won't Resurrect False Ad Suit Over Medical Cream
• UK Litigation Roundup: Here's What You Missed In London
• Judges Who Use Social Media Must Know Their Ethical Limits
• IP Forecast: DC Circ. To Hear Free Speech Challenge To DMCA
• Holmes' 3rd New Trial Bid Targets Missing Database Emails
• Ohio Judge Questions Carveouts In 'Heartbeat' Abortion Law
• GenapSys Gets Court OK For $42M Sale To Investor Group
• SEC To Open New Office Scrutinizing Crypto Filings
• 3rd Circ. Won't Revive Off-Label Suit Over Teva Heart Drug
• Woman Gets 3.5 Years For 'Peddling Drugs' That Hurt Horses
• Baker Botts Snags Former Perkins Coie Managing Partner
• ABA Is Defending Profession's Values From Monied Influences
• Feds Can't Appeal Immunity Ruling In Flint Water Suit
• Bowman And Brooke Partner Discusses Expansion In Austin
• Cherokee Opioids Suit Can't Go To Okla. Court, 10th Circ. Told
• McGuireWoods Adds 2 Patent Pros From Winston & Strawn
• King & Spalding Litigation Team Joins Hogan Lovells In SF
• FTC Says Endo Bankruptcy Can't Stop DC Circ. Appeal
• Elizabeth Holmes Files 2nd New Trial Bid, Citing Balwani Trial
• Analytics Co. Hit With Consumer Suit In Wake Of FTC Action
• Shipping Co. Can't Escape $200M Suit Over Deadly Explosion
• Teva Tells Justices $235M Loss 'Erodes' Patent Law
• Bayer Beats Former Exec's Retaliation Suit At 3rd Circ.
• CVS, Walgreens, Walmart Will Fight $650M Ohio Opioid Order
• How In-House Counsel Can Better Manage Litigation Exposure
• Ill. Pharma Co. Gets OK For Fast Sale Of Testosterone Drug
• Grocer's Amended Suit Stalls Opioid Coverage Ruling
• Merck, Glenmark Antitrust MDL Must Go To Jury, Judge Says
• SF Supervisors OK Psychedelics Decriminalization Measure
• Sidley Taps Former SoftBank Director As Partner In SF
• K&L Gates Clean Energy Projects Atty Jumps To Baker Botts
• J&J, Former Exec Agree To End Workplace Bias Suit
• Pharmacist May Need Third Sentencing In Meningitis Case
• 'Ponzi' Cannabis Extract Suit Belongs In NC, Calif. Judge Says
• Ohio Justices Nix Insurer's Duty To Defend In Opioid Suits
• Pharmacies Flooded NM With Opioids, AG Says As Trial Starts
• Bass Berry 'Lacked Courtesy' As Atty Grieved, DOJ Says
• Ex-Invisalign VP Scored $349K Via Insider Trading, SEC Says
• SEC Fines NY Adviser $1.5M Over Alleged SPAC Conflicts
• 3rd Circ. Panel Questions Niaspan Buyers' Class Data
• Polsinelli Beats Malpractice Suit By Pharma Co., Ex-CEO
• Geron Investors Ink $24M Deal Over Cancer Study Results
• Catching Up With Delaware's Chancery Court
• Ch. 11 Cheat Sheet: Clarus Therapeutics
• Practical E-Discovery Lessons From The Alex Jones Case
• Holmes Wants New Trial After Key Witness Expresses Regrets
• Why Creditors Should Beware Of SBRA Due Diligence Defense
• Barnes & Thornburg Hires Faegre Drinker Team In Philly, NJ
• Pharma Co. Clarus Hits Ch. 11 With Plan To Sell Sole Drug
• EU Bans Illumina's $8B Acquisition Of Grail
• Law360 MVP Awards Go To 188 Attys From 78 Firms
• The Hottest Topics For Health Attys In 2022's Homestretch
• NY Grants $6.5M For Climate Change Insurance Innovation
• Breach Victim Facing 'Imminent' Harm Can Sue, 3rd Circ. Says
• Ohio Clinics Shift Gears In Abortion Ban Challenge
• After Dobbs: State Abortion Ban Fights, Enforcement Heat Up
• USPTO Eases Access To Patents Affected By FDA Delays
• FTC Appealing Judge's Ruling On Illumina's $8B Grail Deal
• Bayer Strikes $40M Deal, Ending 17-Year FCA Saga
• J&J And Ethicon Fight Attempt At New Pelvic Mesh Trial
• 3rd Circ. Preview: J&J Unit, Pipeline Fights On Sept. Docket
• Gov't Wants Max Sentence For Convicted Horse PED Seller
• The Ethical Risks For Lawyers Accepting Payments In Crypto
• Sears, Boy Scouts Each Move Closer To Ch. 11 Resolutions
• Biden Nominates Montana Law Professor For 9th Circ.
• Jury Convicts Arrayit Exec Of Fraud For COVID Test Lies
• EU And Turkey Show How To Break WTO Appeal Impasse
• Harsh Market Limits IPO Prospects For Autumn Listings
• CDC Signs Off On Omicron-Specific COVID Booster Shots
• Philips Unit To Pay $24M To End Med. Supply Kickback Case
• Judge Axes 1 Tyvaso Patent, Finds Another Was Infringed
• Eli Lilly Wants New Trial Over Medicaid Rebate Calculations
• IP Forecast: Patent Biz To Fight For Its Right To Keep Suing
• Monsanto Gets Fast Win In St. Louis Roundup Trial
• Davis Polk, Goodwin Steer $1.1B Novo Nordisk Acquisition
• J&J Reaches $40.5M Opioid Deal With NH, Avoiding Trial
• Maine Pot Org. Seeks Rehearing Of Commerce Clause Ruling
• Bard Can't Escape $3.3M Vein Filter Verdict
• Citing Pot's Illegality, Co. Seeks Quick Win In Patent Row
• Holmes Acquittal Bid Denied As Attys Hint At New Info
• Compliance Considerations For Telehealth Abortion Services
• Envisioning Metaverse-Based Litigation In The Real World
• Cosmetics Cos. Invite Legal Risks With 'Clean' Marketing
• What May Lie Ahead For ITC Trade Secret Claims
• PerkinElmer Says Lab Owes $6M For COVID Test Gear
• FTC Judge Rejects Challenge To Illumina's $8B Grail Deal